Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR
A higher incidence of thyroid C-cell adenomas and carcinoma with use of extended-release exenatide has been seen in rodent studies
Wegovy has been approved for Type 1 diabetes and weight loss, with Ozembic containing lower doses of semaglutide
Completed intakes are typically reviewed within 24 hours